Nektar Therapeutics NKTR Non Cash Interest Expense Related To Sale Of Royalties
Non Cash Interest Expense Related To Sale Of Royalties at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's non cash interest expense related to sale of royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's non cash interest expense related to sale of royalties?
- Nektar Therapeutics (NKTR) reported non cash interest expense related to sale of royalties of $7.94M in Q1 2026.
- How has Nektar Therapeutics's non cash interest expense related to sale of royalties changed year-over-year?
- Nektar Therapeutics's non cash interest expense related to sale of royalties increased by 59.7% year-over-year, from $4.97M to $7.94M.
- What is the long-term trend for Nektar Therapeutics's non cash interest expense related to sale of royalties?
- Over 4 years (2021 to 2025), Nektar Therapeutics's non cash interest expense related to sale of royalties has grown at a -13.7% compound annual growth rate (CAGR), from $47.31M to $26.18M.
- What does non cash interest expense related to sale of royalties mean?
- This metric represents the non-cash interest expense associated with financing arrangements backed by future royalty streams. It reflects the cost of capital for monetization deals where the company receives upfront cash in exchange for future revenue rights. Investors track this to understand the impact of debt-like financing structures on the company's bottom line without immediate cash outflows.